Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Transplant Oncology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3948

Share This Special Issue

Special Issue Editors

Dr. Andrea Dell'Amore

E-Mail Website
Guest Editor

Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health—DSCTV, University of Padova, 35122 Padova, Italy
Interests: heart transplantation; lung transplantation; heart and lung transplantation; pulmonary artery hypertension; pul-monary thromboendoarterctomy; ECMO; cardiac assistance devices; tracheal surgery; robotic surgery; minimally invasive cardiothoracic surgery
Special Issues, Collections and Topics in MDPI journals

Dr. Eleonora Faccioli

E-Mail Website
Guest Editor

Thoracic Surgery Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health–DSCTV, University of Padova, 35122 Padova, Italy
Interests: lung transplant; ECMO; lung cancer; thoracic oncology; minimally invasive thoracic surgery

Dr. Alessio Campisi

E-Mail Website
Guest Editor

Department of Thoracic Surgery, University and Hospital of Trust-Ospedale Borgo Trento, Piazzale Aristide Stefani 1, 37126 Verona, Italy
Interests: minimally invasive lung cancer treatment; lung transplant; thoracic oncology; robotic surgery

Special Issue Information

Dear Colleagues,

Lung transplantation and lung cancer appear to be two distinct topics that require very different treatments and management. Anyone involved in lung transplantation programs is aware of the risk of having transplant patients with lung cancer. In fact, there are at least four clinical scenarios that combine lung transplantation and lung cancer. The first is that of a patient who in the past had and was treated for lung cancer and who is now, for various reasons, a possible candidate for lung transplantation. The second scenario is that of the lung transplant patient where an occult lung neoplasm is found on the explanted native lung. The third scenario is that of the lung transplant patient who develops lung cancer in the medium-long term follow-up. The rarest scenario is the planned transplantation for patients with lung cancer. Could lung transplantation be a curative option in selected cases?

The purpose of this Special Issue is to collect experiences in each of these scenarios which do not yet have well-defined management or treatment guidelines. Original works of an oncological, surgical, and ethical nature will be considered in order to explore the clinical practice of centers with experience in this field.

Dr. Andrea Dell'Amore
Dr. Eleonora Faccioli
Dr. Alessio Campisi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

organ transplantation
lung cancer
lung transplant
transplant oncology
transplant complication

Published Papers (4 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

11 pages, 1397 KiB

Open AccessArticle

Lung Resection for Non-Small Cell Lung Cancer following Bronchoscopic Lung Volume Reduction for Heterogenous Emphysema

by Alfonso Fiorelli, Beatrice Leonardi, Gaetana Messina, Luca Luzzi, Piero Paladini, Chiara Catelli, Fabrizio Minervini, Peter Kestenholz, Leonardo Teodonio, Antonio D’Andrilli, Erino Angelo Rendina and Giovanni Natale

Cancers 2024, 16(3), 605; https://doi.org/10.3390/cancers16030605 - 31 Jan 2024

Viewed by 769

Abstract

Bronchoscopic lung volume reduction (BLVR) is a minimally invasive treatment for emphysema. Lung cancer may be associated with emphysema due to common risk factors. Thus, a growing number of patients undergoing BLVR may develop lung cancer. Herein, we evaluated the effects of lung resection for non-small cell lung cancer in patients undergoing BLVR. The clinical data of patients undergoing BLVR followed by lung resection for NSCLC were retrospectively reviewed. For each patient, surgical and oncological outcomes were recorded to define the effects of this strategy. Eight patients were included in our series. In all cases but one, emphysema was localized within upper lobes; the tumor was detected during routine follow-up following BLVR and it did not involve the treated lobe. The comparison of pre- and post-BLVR data showed a significant improvement in FEV1 (29.7 ± 4.9 vs. 33.7 ± 6.7, p = 0.01); in FVC (28.5 ± 6.6 vs. 32.4 ± 6.1, p = 0.01); in DLCO (31.5 ± 4.9 vs. 38.7 ± 5.7, p = 0.02); in 6MWT (237 ± 14 m vs. 271 ± 15 m, p = 0.01); and a reduction in RV (198 ± 11 vs. 143 ± 9.8, p = 0.01). Surgical resection of lung cancer included wedge resection (n = 6); lobectomy (n = 1); and segmentectomy (n = 1). No major complications were observed and the comparison of pre- and post-operative data showed no significant reduction in FEV1% (33.7 ± 6.7 vs. 31.5 ± 5.3; p = 0.15) and in DLCO (38.7 ± 5.7 vs. 36.1 ± 5.4; p = 0.15). Median survival was 35 months and no cancer relapses were observed. The improved lung function obtained with BLVR allowed nonsurgical candidates to undergo lung resection for lung cancer. Full article

(This article belongs to the Special Issue Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives)

► Show Figures

Figure 1

14 pages, 1327 KiB

Open AccessArticle

Microscopical Variables and Tumor Inflammatory Microenvironment Do Not Modify Survival or Recurrence in Stage I-IIA Lung Adenocarcinomas

by Andrea Dell’Amore, Alessandro Bonis, Luca Melan, Stefano Silvestrin, Giorgio Cannone, Fares Shamshoum, Alberto Zampieri, Federica Pezzuto, Fiorella Calabrese, Samuele Nicotra, Marco Schiavon, Eleonora Faccioli, Marco Mammana, Giovanni Maria Comacchio, Giulia Pasello and Federico Rea

Cancers 2023, 15(18), 4542; https://doi.org/10.3390/cancers15184542 - 13 Sep 2023

Viewed by 609

Abstract

Microscopical predictors and Tumor Immune Microenvironment (TIME) have been studied less in early-stage NSCLC due to the curative intent of resection and the satisfactory survival rate achievable. Despite this, the emerging literature enforces the role of the immune system and microscopical predictors as prognostic variables in NSCLC and in adenocarcinomas (ADCs) as well. Here, we investigated whether cancer-related microscopical variables and TIME influence survival and recurrence in I-IIA ADCs. We retrospectively collected I-IIA ADCs treated (lobectomy or segmentectomy) at the University Hospital (Padova) between 2016 and 2022. We assigned to pathological variables a cumulative pathological score (PS) resulting as the sum of them. TIME was investigated as tumor-infiltrating lymphocytes (TILs < 11% or ≥11%) and PD-L1 considering its expression (<1% or ≥1%). Then, we compared survival and recurrence according to PS, histology, TILs and PD-L1. A total of 358 I-IIA ADCs met the inclusion criteria. The median PS grew from IA1 to IIA, indicating an increasing microscopical cancer activity. Except for the T-SUVmax, any pathological predictor seemed to be different between PD-L1 < 1% and ≥1%. Histology, PS, TILs and PD-L1 were unable to indicate a survival difference according to the Log-rank test (p = 0.37, p = 0.25, p = 0.41 and p = 0.23). Even the recurrence was non-significant (p = 0.90, p = 0.62, p = 0.97, p = 0.74). According to our findings, resection remains the best upfront treatment in I-IIA ADCs. Microscopical cancer activity grows from IA1 to IIA tumors, but it does not affect outcomes. These outcomes are also unmodified by TIME. Probably, microscopical cancer development and immune reaction against cancer are overwhelmed by an adequate R0-N0 resection. Full article

(This article belongs to the Special Issue Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives)

► Show Figures

Figure 1

11 pages, 1660 KiB

Open AccessArticle

Influence of De Novo Malignancies on Long-Term Survival after Lung Transplantation

by Eloisa Ruiz, Paula Moreno, Francisco Javier Gonzalez, Alba Maria Fernandez, Benito Cantador, Juan Luis Parraga, Angel Salvatierra and Antonio Alvarez

Cancers 2023, 15(15), 4011; https://doi.org/10.3390/cancers15154011 - 07 Aug 2023

Cited by 2 | Viewed by 1247

Abstract

(1) Background: Malignancies are an important cause of mortality after solid organ transplantation. The purpose of this study was to analyze the incidence of malignancies in patients receiving lung transplants (LT) and their influence on patients’ survival. (2) Methods: Review of consecutive LT from 1994 to 2021. Patients with and without malignancies were compared by univariable and multivariable analyses. Survival was compared with Kaplan-Meier and Cox regression analysis. (3) Results: There were 731 LT malignancies developed in 91 patients (12.4%) with related mortality of 47% (n = 43). Native lung cancer, digestive and hematological malignancies were associated with higher lethality. Malignancies were more frequent in males (81%; p = 0.005), transplanted for emphysema (55%; p = 0.003), with cyclosporine-based immunosuppression (58%; p < 0.001), and receiving single LT (65%; p = 0.011). Survival was worse in patients with malignancies (overall) and with native lung cancer. Risk factors for mortality were cyclosporine-based immunosuppression (OR 1.8; 95%CI: 1.3–2.4; p < 0.001) and de novo lung cancer (OR 2.6; 95%CI: 1.5–4.4; p < 0.001). (4) Conclusions: Malignancies are an important source of morbidity and mortality following lung transplantation that should not be neglected. Patients undergoing single LT for emphysema are especially at higher risk of mortality due to lung cancer in the native lung. Full article

(This article belongs to the Special Issue Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives)

► Show Figures

Figure 1

14 pages, 2319 KiB

Open AccessArticle

Predictors of Long-Term Survival of Thoracoscopic Lobectomy for Stage IA Non-Small Cell Lung Cancer: A Large Retrospective Cohort Study

by Piotr Gabryel, Piotr Skrzypczak, Alessio Campisi, Mariusz Kasprzyk, Magdalena Roszak and Cezary Piwkowski

Cancers 2023, 15(15), 3877; https://doi.org/10.3390/cancers15153877 - 30 Jul 2023

Cited by 2 | Viewed by 888

Abstract

The standard of care for patients with early-stage non-small cell lung cancer (NSCLC) is anatomical lung resection with lymphadenectomy. This multicenter, retrospective, cohort study aimed to identify predictors of 5-year survival in patients after thoracoscopic lobectomy for stage IA NSCLC. The study included 1249 patients who underwent thoracoscopic lobectomy for stage IA NSCLC between 17 April 2007, and December 28, 2016. The 5-year survival rate equaled 77.7%. In the multivariate analysis, higher age (OR, 1.025, 95% CI: 1.002 to 1.048; p = 0.032), male sex (OR, 1.410, 95% CI: 1.109 to 1.793; p = 0.005), chronic obstructive pulmonary disease (OR, 1.346, 95% CI: 1.005 to 1.803; p = 0.046), prolonged postoperative air leak (OR, 2.060, 95% CI: 1.424 to 2.980; p < 0.001) and higher pathological stage (OR, 1.271, 95% CI: 1.048 to 1.541; p = 0.015) were related to the increased risk of death within 5 years after surgery. Lobe-specific mediastinal lymph node dissection (OR, 0.725, 95% CI: 0.548 to 0.959; p = 0.024) was related to the decreased risk of death within 5 years after surgery. These findings provide valuable insights for clinical practice and may contribute to improving the quality of treatment of early-stage NSCLC. Full article

(This article belongs to the Special Issue Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives)

► Show Figures

Journal Menu

Journal Browser

Lung Transplantation and Lung Cancer: Clinical Scenarios, Outcomes and Future Perspectives

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (4 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI